Leukotriene inhibition in hamster periodontitis. A histochemical and morphometric study by Baroukh, B. & Saffar, J. L.
Research Paper
Mediators of Inflammation, 1, 335-339 (1992)
THE effects of leukotriene (LT) inhibition on gingival and
adjacent bone compartments were assessed by using
phenidone (100 mg/kg/d) and ketoconazole (50 mg/kg/d)
given for 4 weeks to periodontitis-affected hamsters. In the
gingiva the two agents significantly decreased PMNL
recruitment and migration and increased the vascular
lumen. At the bone level, they reduced significantly pre-
osteoclast and osteoclast numbers but did not affect osteo-
clast activity. Phenidone had no action on periodontitis
induced inhibition of bone formation; in contrast ketoco-
nazole enhanced formation. As both phenidone and keto-
conazole are unspecific LT inhibitors it cannot be ascer-
tained that the effects observed were actually due to LT
inhibition. However, phenidone and ketoconazole in-
duced changes different from indomethacin used in
previous studies to inhibit the cyclooxygenase pathway.
These discrepancies suggest that LT inhibition occurred
in the present study and that they participate in gingival
inflammation and osteoclastic destruction during hamster
periodontitis.
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Introduction
5-1ipoxygenase (5-LO) metabolites of arachidonic
acid have been identified in high concentrations in
inflamed gingival tissues.
1-3 However, their role in
periodontal inflammation and their contribution to
tissue destruction, if any, remains unknown.
It is only recently that systemic specific LT
inhibitors4 or receptor antagonists have been
developed. However, it was shown that some
nonspecific agents also inhibited in vivo the 5-LO
pathway. These include phenidone6’7 and ketocona-
zole, an antimycotic drug.
8 In this paper it is
reported that both phenidone and ketoconazole
reduced gingival inflammation and osteoclastic
resorption in a well-defined model of periodon-
titis.9,1
Materials and Methods
Forty male golden hamsters (INRA, France), 6
weeks old, were used in this study. At the start of
the experiment, ten animals were separated to
constitute the control group; they were fed a
standard diet for rodents (M25 Extralabo, Pitre-
ment, France) for the whole experimental period.
The other animals were fed the Keyes 2000
diet (U.A.R., France) which promotes bacterial
plaque growth and subsequent periodontitis. After
8 weeks, the periodontitis-affected hamsters were
separated into three equal groups: one group
(group 2) remained treatment-free for the following
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4 weeks; in group 3, phenidone (Sigma, USA),
50mg/kg, diluted in distilled water was in-
traperitoneally injected twice a day [total dose
100 mg/kg/d7] for 4 weeks. In the last group (group
4), animals received 50 rng/kg/d o.s. of ketocona-
zoles diluted in a 5% aqueous gum arabic solution.
This agent was kindly provided by Janssen
Laboratories, France.
Animals were housed in a room exposed to
natural light cycles (light, 10 h; dark, 14 h). Diet
and water were provided ad libitum. At the end of
the experimental period (12 weeks) all animals were
killed under deep anaesthesia with a 8% chloral
hydrate solution (Prolabo, France). Their left
hemi-mandibles were rapidly dissected out and fixed
by immersion for 24 h in cold (4C) formaldehyde,
0.1 M calcium chloride in cacodylate buffer 0.2 M
pH 7.4, rinsed in the same buffer and dehydrated.
They were embedded without demineralization in
glycol methacrylate. Four micron thick sections
were cut in the horizontal plane and stained for acid
phosphatase using naphthol AS-TR phosphate
(Sigma, USA) and hexazotized pararosanilin (Sig-
ma, USA). Non-osteoclastic acid phosphatase was
inhibited with 50 mM L(+ )-tartaric acid (Sigma,
USA) added directly to the substrate solution. This
procedure preserves tartrate resistant acid phospha-
tase, an enzyme specific of the osteoclastic lineage,
and thus reveals only TRAP+ cells, namely
preosteoclasts and osteoclasts. Sections were
counterstained with toluidine blue (pH 3.8).
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Morphometry was performed with the Morpho-
mat 10 System (Zeiss, Germany) on three sections,
28/m from each other, collected according to
standards described elsewhere.1 The following
bone parameters were measured on the periosteal
aspect of the lingual cortex between the first (ml)
and second (m2) molars: (a) number of osteoclasts
per mm of bone surface. We separately registered
two morphologically different cell profiles: the
active osteoclasts (in contact with the bone surface)
and the inactive ones; (b) number of TRAP+
mononuclear precursors per mm of adjacent bone
surface; (c) mean osteoclast-bone interface (OBI),
an index of osteoclast activity, was obtained by
dividing the resorption surface (in mm) by the
number of active osteoclasts (in /m); (d) active
resorption (in percentage of the bone surface
measured); (e) reversal surface which materializes
the metabolic intermediate phase between resorp-
tion and formation (in %); and (f) formation surface
(in %).
On the same sections gingival inflammation was
also assessed with the following parameters: (a) area
of pocket epithelium surrounding ml (in mm2); (b)
area of infiltrated connective tissue (ICT) identified
as gingival subepithelial connective tissue contain-
ing inflammatory cells and exhibiting oedema and
collagen rarefaction (in mm2); (c) percentage of
vessels in ICT; (d) mean vascular lumen (in/m2);
(e) number of PMNLs adherent to the vascular
endothelium (in cells per vessel); (f) number of
PMNLs in ICT (in cells for mm
2 of ICT); and (g)
area of PMNL aggregated in the pocket space (in
mm2).
Data were statistically compared with one-way
analyses of variance. When significant, Dunnett
t-tests were performed. Results were accepted as
significant at p_< 0.05. They are given as
mean + SEM.
Results
Gingival inflammation parameters: In the control
animals, no periodontal pocket, a major component
of periodontitis, was present. In contrast in all
periodontitis-affected animals, a periodontal pocket
always surrounded the roots of the first molar, the
root surface was then covered by bacterial plaque.
Aggregated PMNLs were interposed between the
bacterial plaque and the pocket epithelium.
The increase in pocket epithelium area was
marked between control and experimental animals
(p < 0.001). The two agents did not change this
parameter. Periodontitis dramatically increased
ICT (12 x, p < 0.001). Phenidone decreased it
(-33% vs group 2), but not significantly. In
contrast, ketoconazole further increased ICT
(+30% vs group 2); this variation also was not
significant. As a consequence the two treated
groups were statistically different (p < 0.01)
(Table 1).
Blood vessels occupied 5.92% of ICT in
controls (Table 1). Periodontitis increased it up to
9.90%, although not significantly. The two
treatments further increased the percentage of
vessels in ICT, however only the phenidone
group was significantly different from group 2
(p < 0.05). The mean vascular lumen increased
significantly in untreated animals (+160% vs
controls, p < 0.01). Both phenidone and ketocona-
zole induced an additional increase (Table 1), but
only ketoconazole-treated hamsters differed from
untreated ones (p < 0.05).
The number of PMNLs adherent to the
vascular endothelium (Table 2) augmented in
periodontitis-affected hamsters compared with
controls but not significantly. The two treatments
lowered this parameter (phenidone: 46%
(p < 0.02) and ketoconazole: -37% (p < 0.05)
vs group 2) below the control level. PMNLs in
ICT were 8.7-fold higher in untreated than in
control animals (p<0.001). The two agents
reduced them (phenidone: --59%, ketoconazole:
--45% vs untreated animals, p < 0.01), but not
to the control level. PMNL accumulation within
the pocket space was also significantly reduced:
-75% with phenidone (p < 0.01) and --54%
with ketoconazole (p < 0.05) versus untreated
animals (Table 2).
Bone parameters" Cell changes are outlined in Table 3.
In control animals no osteoclast was found in the
Table 1. Infiltrated connective tissue (ICT) changes in the different groups. Vessels counted were those
present in the ICT
Control Periodontitis Periodontitis + Periodontitis +
phenidone ketoconazole
ICT (mm2) 0.05 + 0.02 0.63 + 0.09 0.42 -t- 0.095
Vascular area (#m2) 175.38 -I- 20.19 462.50 _+ 43.835 575.12 -I- 51.47
Vessels in ICT (%) 5.92 + 1.20 9.90 + 1.1 2 14.78 + 1.375,d
a, b and c different from controls at p<0.05, p<0.01, p<0.001 respectively;
untreated periodontitis animals (p < 0.01 and e from phenidone-treated hamsters (p < 0.01 ).
0.83 + 0.12c,e
616.89 + 51.89c,a
11.56 __+ 1.85
d different from
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Table 2. Variations in PMNLs in the gingival compartment of the diseased periodontium. The main effect of
both phenidone and ketoconazole concerned PMNL recruitment in the inflamed site
Control Periodontitis Periodontitis + Periodontitis +
phenidone ketoconazole
Marginating PMNLs 0.86 + 0.15 1.28 _+ 0.18 0.69 +_ 0.08d 0.80 +__ 0.17
(cells/vessel)
PMNLs in ICT 60.56 + 26.34 531.75 + 92.865 215.75 __+ 27.57 293.96 + 37.20a,
(cells/mm2)
PMNLs around 0.00 __+ 0.00 0.11 + 0.035 0.03 -I- 0.01 0.05 + 0.02
plaque (mm2)
a and b different from group controls at p < 0.05, p < 0.001" c, d and e different from affected untreated
animals at p < 0.05, p < 0.02 and p < 0.01, respectively.
Table 3. Changes in osteoclastic cells along the periosteal bone surface adjacent to ICT. Both
preosteoclasts and osteoclasts were reduced, although their decreases did not reach the control levels
Control Periodontitis Periodontitis + Periodontitis +
phenidone ketoconazole
Total osteoclasts 0.00 -I- 0.00 7.87 + 1.05b 4.63 -I- 0.73a,c 4.55 + 0.68a’c
(cells/mm)
Active osteoclasts 0.00 + 0.00 5.30 _+ 0.495 3.26 ___
0.23a’c 3.40 __+ 0.79a,c
(cells/mm)
Preosteoclasts 0.61 -I- 0.61 35.36 __+ 2.555 10.90 __+ 2.05a’d 15.14 -t- 1.66a,d
(cells/mm)
a and b different from group controls at p < 0.01 and p < 0.001’ c and d different from affected
untreated animals at p < 0.02 and p < 0.001.
reference bone segment. Periodontitis caused a
dramatic increase in the total number of osteoclasts.
They were similarly reduced by the two agents
(p < 0.02), but remained at a rather high level
compared with controls. Active profiles decreased
in the same proportion with the two agents
(p < 0.02). Inactive profiles also decreased but their
variations were not significant. The ratio active/in-
active profiles was 2.06 in untreated animals, 2.37
with phenidone and 2.9 with ketoconazole. The
mean OBI was not statistically modified by the
treatments. Preosteoclasts increased 58 times in un-
treated animals compared with controls (p < 0.001).
Phenidone and ketoconazole reduced preosteo-
clasts by 69% and 57% respectively (p < 0.001).
Surface activity changes are outlined in Table 4.
In the untreated animals, resorption occupied
15.17% of the bone surface. The two a.gents reduced
it by 50% (p <0.01). Reversal increased in
untreated animals by 9.4-fold (p < 0.001 vs
controls). It was not significantly modified with
phenidone, in contrast ketoconazole decreased it
(-34%, p < 0.01). The discrepancy between the
treated groups made them significantly different
(p < 0.02).
Formation was the main bone surface activity in
controls; periodontitis almost completely abolished
it (-88%, p < 0.01). Unlike phenidone, ketocona-
zole partially reversed the effect of periodontitis as
a conspicuous increase in formation occurred in this
treatment group (p < 0.05 vs group 2). As a
consequence, the action of the two agents was
significantly different (p < 0.05).
Some gingival and bone parameters were
statistically related. The more significant relation-
ships concerned the number ofPMNLs in ICT and
Table 4. Variations in bone surface activity parameters. The two agents had opposite actions on
formation: phenidone had no effect on the uncoupling due to periodontitis while ketoconazole
induced a significant increase in formation
Control Periodontitis Periodontitis + Periodontitis +
phenidone ketoconazole
Resorption 0.00 + 0.00 15.17 __+ 1.81 7.78 + 1.07a’d 7.18 + 1.65a’d
Reversal 4.81 + 2.85 45.21 +_ 4.065 50.27 + 6.985 29.68 + 6.92a,f
Formation 35.80 + 6.25 4.08 + 2.67 5.50 __+ 3.55 25.82 -I- 9.01 c,
a and b different from group controls at p<0.01 and p<0.001’ c and d different from
affected untreated animals at p < 0.05 and p < 0.01" e and different from phenidone-treated
hamsters at p < 0.05 and p < 0.02.
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respectively the extent of resorption (r 0.66;
p 0.0001), and the total number of osteoclasts
(r 0.49; p 0.008). Preosteoclasts and total
osteoclasts were also statistically related (r--0.65;
p 0.0001).
Discussion
Taken together the results show that the two
unspecific LT inhibitors had conspicuous actions on
both gingival and bone changes due to peri-
odontitis. This suggests that LTs might be involved
in hamster periodontitis, a statement in agreement
with observations showing that LT concentrations
increased in gingival tissues during periodontitis.
1-3
At the gingival level the more striking action of the
two agents consisted in a prominent decrease in
PMNLs in the three compartments being invest-
igated, viz adherent to blood vessel endothelium,
infiltrating the gingival connective tissue, and
aggregated in the pocket space. This was primarily
due to a marked depression in PMNL recruitment
and penetration in the site as shown by the
reduction in adherent PMNLs. Therefore, pheni-
done and ketoconazole inhibited PMNL chemo-
taxis, an action generally assigned to LTB4.11 LTB4
would be released either by endothelial cells
2 or by
cells of the extravascular compartment such as
PMNLs,
3 monocytes and macrophages,14’s and
epithelial cells.6 Besides LTB4, stimulated en-
dothelial cells would release other unidentified
lipoxygenase-derived PMNL chemoattractants. 17
The reduction in PMNLs aggregated in the
pocket space was in proportion more marked than
in ICT although the mass of bacteria was not
modified (data not shown). As epithelial cells release
LTB4 when properly activated,
6 phenidone and
ketoconazole may have disturbed an epithelial
chemotactic gradient governing PMNL emigration
towards bacteria.
The partial inhibition of PMNL chemotaxis
indicates that several mediators attracted PMNLs in
the gingival tissues. Besides LTs, inflammatory and
resident ceils release other potent PMNL chemoat-
tractants such as IL-lfl and TNF,8’9 CSa,
20 C3b,
9
serotonin.
7 Prostanoids also promote PMNL
recruitment,
2 in this model cyclooxygenase (CO)
inhibition reduced PMNL aggregation in the
pocket.
22
Oedema is another component of gingival
inflammation possibly mediated by LTs. Inhibition
of the LT-dependent endothelial leakage may have
led to the reduction in ICT in the phenidone-treated
animals. However, the increase in ICT in the
ketoconazole-treated group is puzzling in this view.
Phenidone and ketoconazole induced vasodilata-
tion, in fact LTC4 and LTD4 are vasoconstrictors.
1
The higher e(fectiveness of ketoconazole might be
due to its wider spectrum of activity as it also
inhibits TXAi,8’23 a vasoconstrictor.24 The increase
in the percentage of .vessels in the two treated
groups might be due to vessel proliferation in the
treated groups, however as LTC4 is a promoter of
endothelial cell proliferation,
is such an effect can be
excluded under LT inhibition. Alternatively, the
increase in vessels might only be relative with
phenidone; larger vessels in less ICT may induce
an apparent increase in vessels. With ketoconazole
the potential incidence of the more intense
vasodilatation on this parameter was possibly
lessened by the increase in ICT.
At the bone level the more conspicuous effect
was the reduction in osteoclastic resorption. This
result is consistent with the observation that LTB4
and the peptido-LTs stimulated bone resorption
in vitro,
26 through modifications in the concentration
of osteoblast intracellular calcium.7 These observa-
tions support the contention that LTs directly
stimulate resorption. However, the effects on
resorption might be indirect. The decrease in
differentiated osteoclasts was indeed related to the
reduction in PMNLs present at the site taken as an
index of gingival inflammation, suggesting that the
higher the inflammatory reaction, the greater the
number of osteoclasts in the site and the higher the
level of resorption. On the other hand, the two
agents may have inhibited in cascade the release of
other mediators of resorption. As a matter of fact,
LTB4 and LTD4 are involved in the production of
IL-1 by endotoxin-stimulated monocytes
28 via a
mobilization of intracellular calcium.
29 The role of
IL-1 as a promotor ofresorption is well documented.
However, the role, if any, of LTs in resorption is
still unknown. The relationship found between
osteoclasts and preosteoclasts, which is a character-
istic of hamster periodontitis, indicates that
phenidone and ketoconazole did not impair the
differentiation of preosteoclasts into osteoclasts, and
the process of multinucleation.
The main problem with regard to the present
results is whether the two agents inhibited only LTs
or both 5-LO and CO pathways. Indeed, Blackwell
and Flower
6 stated that phenidone inhibited the two
pathways in the same extent. However, Carlson
et a].7 showed in the rat that phenidone had a potent
inhibitory activity against 5-LO but was only a
weak CO inhibitor. In this model of periodontitis,
when the bone effects of the disease were inhibited
with the CO inhibitor indomethacin, formation was
restored beyond the control level22’3 showing that
prostanoids were involved in the uncoupling
between resorption and formation, another char-
acteristic feature of periodontitis.
9 Coupling refers
of the events ensuring the focal recruitment and
proliferation of osteoblast precursors and the
expression of the osteoblast phenotype. In the
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present study phenidone was quite unable to
activate formation indicating that it had no action
on prostanoid-induced uncoupling. This data
suggests that LTs are actually not involved in
periodontitis coupling disturbances. On the other
hand in two non-inflammatory models of bone
resorption, indomethacin lowered the ratio acti-
ve/inactive osteoclasts.32’33 Conversely, in the
present study the ratio was increased, slightly with
phenidone and more markedly with ketoconazole.
Indomethacin also reduced osteoclast activity
(Leroux and Saffar, submitted for publication) while
phenidone and ketoconazole did not. Therefore the
effects on osteoclast parameters of indornethacin on
one hand and phenidone and ketoconazole on the
other hand were quite different. In addition, in a
non-inflammatory model of resorption, we ob-
served with a specific 5-LO inhibitor, the same
changes in TRAP+ preosteoclasts and osteoclasts
as in the present study (C. Franchi, unpublished
data). These observations led us to assume that, at
least at the bone level, the changes induced by
phenidone were not due to prostanoid inhibition
but rather were LT related. Ketoconazole is a less
effective inhibitor of LT synthesis than phenidone,
8
it also inhibits TXA2 synthesis probably through
an interaction with the cytochrome P-4508’23 It may
thus be anticipated that ketoconazole inhibited
concomitantly several mediators, which might
explain some discrepancies between phenidone and
ketoconazole at both gingival and bone levels. In
particular, like indomethacin, ketoconazole induced
an increase in formation, although to a lesser extent.
To the authors’ knowledge the precise action of
TXA2 on bone formation has not been determined,
thus an effect of ketoconazole on formation through
TXA2 inhibition remains speculative. On the other
hand, ketoconazole interferes with the metabolism
of 1,25 (OH)iD in osteoblast-like cells
34 and this
action might contribute to the increase in formation
in this group.
References
1. Scott S, Odle B, Offenbacher S. Inflamed periodontal tissues contain high
levels of leukotriene B4. J Dent Res 1985: 64:377 (abstract).
2. E1 Attar TMA, Lin HS, Killoy WJ, Vanderhoek Y, Goodson JM. Hydroxy
fatty acids and prostaglandin formation in diseased human periodontal pocket
tissue. J Period Res 1986; 21: 169-176.
3. Offenbacher S, Odle BM, Van Dyke TE. Steady state levels of leukotrienes
B4, C4, D4, and E4 in periodontal tissues. J Dent Res 1986; 65:756 (abstract).
4. Tateson JE, Randall RW, Reynolds CH, et al. Selective inhibition of
arachidonate 5-1ipoxygenase by novel acetohydroxamic acids: biochemical
assessment in vitro and vivo. Br J Pbarmaco11988; 94: 528-539.
5. Snyder DW, Fleisch JH. Leukotriene receptor antagonists potential
therapeutic agents. Ann Rev Pharmacol Toxicol 1989; 29: 123-143.
6. Blackwell GJ, Flower RJ. 1-Phenyl-3-pyrazolidone: inhibitor of
cyclo-oxygenase and lipoxygenase pathways in lung and platelets.
Prostaglandins 1978; 16: 417-425.
7. Carlson RP, O’Neill-Davis L, Chang J, Lewis AJ. Modulation of
edema by cyclooxygenase and lipoxygenase inhibitors and other
pharmacologic agents. Agents Actions 1985; 17: 197-204.
8. Beetens JR, Loots W, Somers Y, Coene MC, de Clerck F. Ketoconazole
inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharm
1986; 35: 883-891.
9. Makris GP, Saffar JL. Disturbances in bone remodeling during the progress
of hamster periodontitis. A morphological and quantitative study. J Period
Res 1985; 20: 411-420.
10. Baroukh B, Saffar JL. Identification of osteoclasts and their mononuclear
precursors. A comparative histological and histochemical study in hamster
periodontitis. J Period Res 1991; 26: 161-166.
11. Dahlen SE, Bj6rk J, Hedqvist P, et al. Leukotrienes promote plasma leakage
and leukocyte adhesion in postcapillary venules: in vivo effects with relevance
to the acute inflammatory response. Proc Natl Acad Sci USA 1981; 78:
3887-3891.
12. Nolan KD, Keagy BA, Ramadan FM, Johnson G, Henke DC. Endothelial
cells synthesize leukotriene-B4. J Vasc Surg 1990; 12: 298-304.
13. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH.
Leukotriene B, potent chemokinetic and aggregating substance released
from polymorphonuclear leukocytes. Nature 1980; 286: 264-265.
14. Fels AOS, Pawlowski NA, Cramer EB, King ZA, Scott WA. Human alveolar
macrophages produce leukotriene B4. Proc NaN Acad Sci USA 1982; 79:
7866-7870.
15. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human
monocytes stimulation of their phagocytic receptor for particulate
activators. J Immuno11984; 132: 3034-3040.
16. Brain SD, Camp RDR, Leigh IM, Ford-Hutchinson AW. The synthesis of
leukotriene B4-1ike material by cultured human keratinocytes. J Invest
Dermato11982; 78: 328 (abstract).
17. Charles A, Rounds S, Farber HW. Neutrophil chemoattractant production
by cultured serotonin-stimulated bovine and human endothelial cells. Am J
Physio11991 261: L133-L139.
18. Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin and tumor
necrosis factor stimulate human vascular endothelial cells to promote
transendothelial neutrophil passage. J Clin Invest 1989; 83: 444-455.
19. Ward PA, Marks RM. The acute inflammatory reaction. Curr Opin Immunol
1989; 2: 5-9.
20. McMillan RM, Foster SJ. Leukotriene B4 and inflammatory disease. Agents
Actions 1988; 24: 114-119.
21. Palder SB, Huval W, Lelcuk S, et al. Reduction of polymorphonuclear
leukocyte accumulation by inhibition of cyclooxygenase and thromboxane
synthase in the rabbit. Surgery 1986; 99: 72-80.
22. Carter-Bartlett P, Dersot JM, Saffar JL. Periodontal and femoral bone status
in periodontitis-affected hamsters receiving high dose indomethacin
treatment. J Biol Buccale 1989; 17: 93-101.
23. Dunham BM, Hechtman HB, Valeri CR, Shepro D. Antiinflammatory agents
inhibit microvascular permeability induced by leukotrienes and by stimulated
human neutrophils. Microcirc Endoth Lymph 1984; 1: 465-489.
24. Davies P, Bailey PJ, Goldenberg MM. The role of arachidonic acid
oxygenation products in pain and inflammation. Ann Rev Immunol 1984; 2:
335-357.
25. Modat G, Muller A, Mary A, Bonne C. LTC4, but not LTB4, binds vascular
endothelial cells and promotes their proliferation in vitro. Ann New York
Acad Sci 1988; 524: 414-416.
26. Meghji S, Sandy JR, Scutt AM, Harvey W, Harris M. Stimulation of bone
resorption by lipoxygenase metabolites of arachidonic acid. Prostaglandins
1988; 36: 139-149.
27. Sandy JR, Meikle MC, Martin BR, Farndale RW. Leukotriene B4 increases
intracellular calcium concentration and phosphoinositide metabolism in
osteoblasts via cyclic adenosine 3’,5’-monophosphate-independent
pathways. Endocrinolog 1991; 129: 582-590.
28. Rola-Pleszczynski M, Lemaire I. Leukotrienes augment interleukin
production by human monocytes. J Immuno11985; 6: 3958-3961.
29. Tatsuno I, Saito H, Chang KJ, Tamura Y, Yoshida S. Comparison of the
effect between leukotriene B4 and leukotriene B5 the induction of
interleukin l-like activity and calcium mobilizing activity in human blood
monocytes. Agents Actions 1990; 29: 324-327.
30. Saffar JL, Lasfargues JJ. A histomorphometric study of the effect of
indomethacin and calcitonin bone remodelling in hamster periodontitis.
Archs Oral Bio11984; 29: 555-558.
31. Parfitt AM. The cellular basis of bone remodeling: the quantum concept
reexamined in light of recent advances in the cell biology of bone. Calcif
Tissue Int 1984; 36: 37--45.
32. Saffar JL, Leroux P. Role of prostaglandins in bone resorption in
synchronized remodeling sequence in the rat. Bone 1988; 9: 141-145.
33. Lasfargues j, Saffar JL. Effects of prostaglandin inhibition the bone
activities associated with the spontaneous drift of molar teeth in the rat.
Anatomical Record 1992; (in press).
34. Reinhardt TA, Horst RL. Ketoconazole inhibits self-induced metabolism of
1, 25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor
up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989; 272:
459-465.
Received 30 June 1992;
accepted in revised form 30 July 1992
Mediators of Inflammation-Vol 1992 339